Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Ito Y, Vertosick EA, Sjoberg DD, Vickers AJ, Al-Ahmadie HA, Chen YB, Gopalan A, Sirintrapun SJ, Tickoo SK, Eastham JA, Scardino PT, Reuter VE, Fine SW.

Am J Surg Pathol. 2019 May 17. doi: 10.1097/PAS.0000000000001291. [Epub ahead of print]

PMID:
31107718
2.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 May 6. pii: 201902651. doi: 10.1073/pnas.1902651116. [Epub ahead of print]

3.

JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.

Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Blum KA, Lohse CM, Hakimi AA, Thompson RH, Leibovich BC, Berger MF, Arcila ME, Ross DS, Ladanyi M, Antonescu CR, Reuter VE.

Mod Pathol. 2019 Apr 17. doi: 10.1038/s41379-019-0269-x. [Epub ahead of print]

PMID:
30996253
4.

Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.

Jia L, Carlo MI, Khan H, Nanjangud GJ, Rana S, Cimera R, Zhang Y, Hakimi AA, Verma AK, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, Tickoo SK, Reuter VE, Gartrell BA, Chen YB.

Mod Pathol. 2019 Apr 12. doi: 10.1038/s41379-019-0273-1. [Epub ahead of print]

PMID:
30980040
5.

A comparison of adult rhabdomyosarcoma and high grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.

Gupta S, Sosa CP, Kosari F, Folpe A, Bhinge KN, Yang L, Agahi A, Johnson SH, Frank I, Boorjian SA, Hansel DE, Al-Ahmadie HA, Reuter VE, Vasmatzis G, Jimenez RE, Herrera-Hernandez L, Cheville JC.

Hum Pathol. 2019 Apr 1. pii: S0046-8177(19)30052-8. doi: 10.1016/j.humpath.2019.03.007. [Epub ahead of print]

PMID:
30946934
6.

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma.

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, Stirdivant S, Tang J, Schultz N, Jeng P, Dong Y, Su W, Cheng EH, Russo P, Coleman JA, Papaemmanuil E, Chen YB, Reuter VE, Sander C, Kennedy SR, Hsieh JJ, Lyssiotis CA, Tickoo SK, Hakimi AA.

Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986.

7.

Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.

Isharwal S, Hu W, Sarungbam J, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Jadallah S, Loo FL, Pietzak EJ, Cha EK, Bochner BH, Berger MF, Iyer G, Solit DB, Reuter VE, Al-Ahmadie H.

J Pathol. 2019 Mar 5. doi: 10.1002/path.5261. [Epub ahead of print]

PMID:
30838648
8.

Whole slide imaging equivalency and efficiency study: experience at a large academic center.

Hanna MG, Reuter VE, Hameed MR, Tan LK, Chiang S, Sigel C, Hollmann T, Giri D, Samboy J, Moradel C, Rosado A, Otilano JR 3rd, England C, Corsale L, Stamelos E, Yagi Y, Schüffler PJ, Fuchs T, Klimstra DS, Sirintrapun SJ.

Mod Pathol. 2019 Feb 18. doi: 10.1038/s41379-019-0205-0. [Epub ahead of print]

PMID:
30778169
9.

Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.

Sarungbam J, Mehra R, Tomlins SA, Smith SC, Jayakumaran G, Al-Ahmadie H, Gopalan A, Sirintrapun SJ, Fine SW, Zhang Y, Amin MB, Reuter VE, Chen YB, Tickoo SK.

Mod Pathol. 2019 May;32(5):701-709. doi: 10.1038/s41379-018-0185-5. Epub 2019 Jan 8.

PMID:
30622286
10.

Non-urothelial carcinomas of the bladder.

Park S, Reuter VE, Hansel DE.

Histopathology. 2019 Jan;74(1):97-111. doi: 10.1111/his.13719. Review.

PMID:
30565306
11.

Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.

Signoretti S, Flaifel A, Chen YB, Reuter VE.

J Clin Oncol. 2018 Oct 29:JCO2018792259. doi: 10.1200/JCO.2018.79.2259. [Epub ahead of print]

PMID:
30372384
12.

Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.

Chen YB, Mirsadraei L, Jayakumaran G, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, Tickoo SK, Reuter VE.

Am J Surg Pathol. 2019 Jan;43(1):121-131. doi: 10.1097/PAS.0000000000001170.

PMID:
30303819
13.

Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer.

Ito Y, Udo K, Vertosick EA, Sjoberg DD, Vickers AJ, Al-Ahmadie HA, Chen YB, Gopalan A, Sirintrapun SJ, Tickoo SK, Scardino PT, Eastham JA, Reuter VE, Fine SW.

J Urol. 2019 Mar;201(3):535-540. doi: 10.1016/j.juro.2018.09.060.

PMID:
30300632
14.

VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney.

Wang L, Zhang Y, Chen YB, Skala SL, Al-Ahmadie HA, Wang X, Cao X, Veeneman BA, Chen J, Cieślik M, Qiao Y, Su F, Vats P, Siddiqui J, Xiao H, Sadimin ET, Epstein JI, Zhou M, Sangoi AR, Trpkov K, Osunkoya AO, Giannico GA, McKenney JK, Argani P, Tickoo SK, Reuter VE, Chinnaiyan AM, Dhanasekaran SM, Mehra R.

Am J Surg Pathol. 2018 Dec;42(12):1571-1584. doi: 10.1097/PAS.0000000000001150.

PMID:
30285995
15.

Novel MEIS1-NCOA2 Gene Fusions Define a Distinct Primitive Spindle Cell Sarcoma of the Kidney.

Argani P, Reuter VE, Kapur P, Brown JE, Sung YS, Zhang L, Williamson R, Francis G, Sommerville S, Swanson D, Dickson BC, Antonescu CR.

Am J Surg Pathol. 2018 Nov;42(11):1562-1570. doi: 10.1097/PAS.0000000000001140.

PMID:
30179902
16.

Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla.

Mazaheri Y, Shukla-Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, Akin O, Hricak H.

Magn Reson Imaging. 2019 Jan;55:93-102. doi: 10.1016/j.mri.2018.08.025. Epub 2018 Aug 31.

PMID:
30176373
17.

Granular Cell Tumor of the Bladder: A Report of Six Cases.

Sun Y, Reuter VE, Magi-Galluzzi C, Sankin A, Epstein JI.

Urology. 2018 Nov;121:203.e1-203.e5. doi: 10.1016/j.urology.2018.08.018. Epub 2018 Aug 29.

PMID:
30170086
18.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

19.

Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.

Dean LW, Assel M, Sjoberg DD, Vickers AJ, Al-Ahmadie HA, Chen YB, Gopalan A, Sirintrapun SJ, Tickoo SK, Eastham JA, Scardino PT, Reuter VE, Ehdaie B, Fine SW.

J Urol. 2019 Jan;201(1):77-82. doi: 10.1016/j.juro.2018.07.062.

PMID:
30076908
20.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

21.

Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM; Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA.

Cell Rep. 2018 Jun 12;23(11):3392-3406. doi: 10.1016/j.celrep.2018.05.039.

22.

Comedonecrosis Revisited: Strong Association With Intraductal Carcinoma of the Prostate.

Fine SW, Al-Ahmadie HA, Chen YB, Gopalan A, Tickoo SK, Reuter VE.

Am J Surg Pathol. 2018 Aug;42(8):1036-1041. doi: 10.1097/PAS.0000000000001104.

PMID:
29878934
23.

Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists.

Williamson SR, Rao P, Hes O, Epstein JI, Smith SC, Picken MM, Zhou M, Tretiakova MS, Tickoo SK, Chen YB, Reuter VE, Fleming S, Maclean FM, Gupta NS, Kuroda N, Delahunt B, Mehra R, Przybycin CG, Cheng L, Eble JN, Grignon DJ, Moch H, Lopez JI, Kunju LP, Tamboli P, Srigley JR, Amin MB, Martignoni G, Hirsch MS, Bonsib SM, Trpkov K.

Am J Surg Pathol. 2018 Sep;42(9):1253-1261. doi: 10.1097/PAS.0000000000001087.

PMID:
29878933
24.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. Erratum in: Cell Rep. 2018 Jun 19;23(12):3698.

25.

Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA.

Hum Pathol. 2018 Jul;77:63-69. doi: 10.1016/j.humpath.2018.03.015. Epub 2018 Mar 27.

PMID:
29601842
26.

Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features.

Ren Q, Wang L, Al-Ahmadie HA, Fine SW, Gopalan A, Sirintrapun SJ, Tickoo SK, Reuter VE, Chen YB.

Am J Surg Pathol. 2018 Jun;42(6):767-777. doi: 10.1097/PAS.0000000000001038.

PMID:
29462091
27.

NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors.

Dickson BC, Sung YS, Rosenblum MK, Reuter VE, Harb M, Wunder JS, Swanson D, Antonescu CR.

Am J Surg Pathol. 2018 May;42(5):636-645. doi: 10.1097/PAS.0000000000001021.

28.

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB.

Am J Surg Pathol. 2018 Mar;42(3):279-292. doi: 10.1097/PAS.0000000000001000.

PMID:
29309300
29.

Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jun;199(6):1502-1509. doi: 10.1016/j.juro.2017.12.056. Epub 2018 Jan 4.

PMID:
29307681
30.

Urothelial neoplasms in pediatric and young adult patients: A large single-center series.

Saltsman JA, Malek MM, Reuter VE, Hammond WJ, Danzer E, Herr HW, LaQuaglia MP.

J Pediatr Surg. 2018 Feb;53(2):306-309. doi: 10.1016/j.jpedsurg.2017.11.024. Epub 2017 Nov 14.

31.

Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.

Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, Kundra R, Abeshouse A, Viale A, Cha EK, Hao X, Reuter VE, Rudin CM, Bochner BH, Rosenberg JE, Bajorin DF, Schultz N, Berger MF, Iyer G, Solit DB, Al-Ahmadie HA, Taylor BS.

Clin Cancer Res. 2018 Apr 15;24(8):1965-1973. doi: 10.1158/1078-0432.CCR-17-2655. Epub 2017 Nov 27.

32.

Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.

Audenet F, Vertosick EA, Fine SW, Sjoberg DD, Vickers AJ, Reuter VE, Eastham JA, Scardino PT, Touijer KA.

J Urol. 2018 Apr;199(4):961-968. doi: 10.1016/j.juro.2017.10.010. Epub 2017 Oct 10.

33.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033.

34.

Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA.

Eur Urol Focus. 2017 Sep 23. pii: S2405-4569(17)30212-2. doi: 10.1016/j.euf.2017.09.008. [Epub ahead of print]

35.

Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.

Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P.

Histopathology. 2018 Mar;72(4):588-600. doi: 10.1111/his.13395. Epub 2017 Dec 4.

PMID:
28898443
36.

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.

37.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

Isharwal S, Audenet F, Drill E, Pietzak EJ, Iyer G, Ostrovnaya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, Reuter VE, Bochner BH, Solit DB, Al-Ahmadie HA.

Eur Urol Focus. 2019 Mar;5(2):201-204. doi: 10.1016/j.euf.2017.07.004. Epub 2017 Aug 10.

PMID:
28802642
38.

Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.

Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA.

Eur Urol Focus. 2017 Oct;3(4-5):421-427. doi: 10.1016/j.euf.2016.06.015. Epub 2016 Jul 16.

39.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909. Review.

40.

Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases.

Bennett JA, Weigelt B, Chiang S, Selenica P, Chen YB, Bialik A, Bi R, Schultheis AM, Lim RS, Ng CKY, Morales-Oyarvide V, Young RH, Reuter VE, Soslow RA, Oliva E.

Mod Pathol. 2017 Oct;30(10):1476-1488. doi: 10.1038/modpathol.2017.56. Epub 2017 Jun 30.

41.

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.

Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13.

PMID:
28511883
42.

Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.

Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA.

Nat Commun. 2017 May 10;8:15165. doi: 10.1038/ncomms15165.

43.

Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer.

Shukla-Dave A, Wassberg C, Pucar D, Schöder H, Goldman DA, Mazaheri Y, Reuter VE, Eastham J, Scardino PT, Hricak H.

World J Radiol. 2017 Mar 28;9(3):134-142. doi: 10.4329/wjr.v9.i3.134.

44.

Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists.

Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Kunju LP, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS.

Hum Pathol. 2017 May;63:149-156. doi: 10.1016/j.humpath.2017.03.004. Epub 2017 Mar 14.

45.

RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.

Argani P, Zhang L, Reuter VE, Tickoo SK, Antonescu CR.

Am J Surg Pathol. 2017 May;41(5):655-662. doi: 10.1097/PAS.0000000000000835.

46.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

48.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2016 Nov 17;17(1):231. Erratum in: Genome Biol. 2017 Mar 1;18(1):46.

49.

Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.

Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, Cani AK, Hovelson DH, Omata K, McHugh JB, Jochum W, Colecchia M, Amin M, Divatia MK, Hes O, Menon S, Werneck da Cunha I, Tripodi S, Brimo F, Gill AJ, Osunkoya AO, Magi-Galluzzi C, Sibony M, Williamson SR, Nesi G, Picken MM, Maclean F, Agaimy A, Cheng L, Epstein JI, Reuter VE, Tickoo SK, Tomlins SA, Amin MB.

Am J Surg Pathol. 2016 Nov;40(11):1457-1472.

50.

TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.

Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, Netto GJ, Antonescu CR.

Am J Surg Pathol. 2016 Nov;40(11):1484-1495.

Supplemental Content

Loading ...
Support Center